Smarter Utility

 

TMCNet: Stock Marketing Inc Presents!! VKNG,GHLV,APNT,AEGY,NUBL,CEMI:: Sign Up With Us Today!!

[July 29, 2010]

Stock Marketing Inc Presents!! VKNG,GHLV,APNT,AEGY,NUBL,CEMI:: Sign Up With Us Today!!

(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: VKNG) Viking Systems, Inc., (OTCBB: GHLV) Global Health Ventures, Inc., (OTCBB: APNT) Applied Nanotech Holdings, Inc., (OTCBB: AEGY) Alternative Energy Partners Inc., (OTCBB: NUBL) Numobile, Inc., (OTCBB: CEMI) Chembio Diagnostics, Inc www.StockMarketingInc.com For More Information email us!! Steve@StockMarketingInc.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: VKNG - Viking Systems, Inc.) LATEST NEWS!! Viking Systems and Boston Scientific Extend Supply Contract WESTBOROUGH, Mass., Jul 28, 2010 -- Viking Systems, Inc. (OTCBB: VKNG) announced today an extension of its supply contract with Boston Scientific. Based on the continued success of Boston Scientific's SpyGlass(R) Direct Visualization System, the companies agreed to extend the term of the supply agreement through May 2012.


"We are very pleased to have reached this agreement with Boston Scientific," said Jed Kennedy, President & CEO of Viking Systems, who went on to say, "Our OEM products provide a solid manufacturing base that benefits both our OEM and Viking brand products including our planned Next Generation 3DHD Visualization System. Our relationship with Boston Scientific and our other OEM customers brings further credibility to Viking as a high quality designer and manufacturer of visualization products for the medical markets." Boston Scientific's SpyGlass Direct Visualization System is the latest advancement in intraductal visualization during a cholangioscopy. The SpyGlass System is the first single operator, intraductal system that allows for not only optical viewing, but also optically-guided biopsies and has been shown to be compatible with electrohydraulic lithotripsy (EHL) and holmium laser to fragment stones. Viking Systems provides the camera, lightsource and related accessories designed specifically for the SpyGlass(R) Direct Visualization System.

About Viking Systems, Inc.

Viking Systems, Inc. (OTCBB: VKNG) is a leading worldwide developer, manufacturer and marketer of 2D and 3D visualization solutions for complex minimally invasive surgery. The Company partners with medical device companies and healthcare facilities to provide surgeons with proprietary visualization systems enabling minimally invasive surgical procedures, which reduce patient trauma and recovery time. During 2010 Viking intends to complete the development of its unique Next Generation 3DHD Visualization System and currently plans to launch the system in the fourth quarter of 2010. For more information visit the Company's website at: www.vikingsystems.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: GHLV - Global Health Ventures, Inc.) LATEST NEWS!! Global Health Ventures to Initiate Prototype Manufacturing of a Sublingual Anti-Anxiety Drug VANCOUVER, BRITISH COLUMBIA, Jul 29, 2010 -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company today announced that it has signed an agreement with Carter Pharmaceutical of Toronto, Canada, to manufacture the prototype of its anti-anxiety drug "Relax-B". Together, the companies will manufacture about 10,000 pills for carrying out the necessary testing of the product prior to the initiation of a bioequivalent study in man. The Company plans to carry out the clinical trials of this product in North America under the FDA guideline. This study with Carter Pharmaceuticals is expected to take about two to three months.

"We are pleased to announce that we will initiate the clinical trials for our second drug Relax-B in North America under the FDA guideline. Our first drug X-Excite which is designed for the male sexual enhancement is going through similar studies in Europe. We plan to get some drugs in developmental stages approved in Europe first and then in United States, while some drugs in United States first and then in Europe", said Dr. Hassan Salari, President and CEO.

About Relax-B Relax-B is a sublingual formulation of an already FDA approved drug. The current formulation is used by more than 10 million patients worldwide generating billions of dollars for large pharmaceutical companies. Our formulation that uses our proprietary sublingual technology allows a new market for this drug and is expected to have similar market potential. Anxiety and nervousness is one of the major problems with many people in western countries and we believe that our product can capture enormous market worldwide.

ABOUT GLOBAL HEALTH VENTURES - Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy, heart medication and addiction replacement.

---------------------------------------------------------------------------------------------------------------------------------------------------------------- (OTCBB: APNT - Applied Nanotech Holdings, Inc.) LATEST NEWS!! Applied Nanotech Composite Program to be Presented at Army Science Conference AUSTIN, Texas, Jul 29, 2010 -- Applied Nanotech Holdings, Inc. (OTCBB: APNT) announced that work related to improving the ballistic performance of E-glass composite panels using carbon nanotubes performed in collaboration with the U.S. Army Engineer Research Development Center -- Construction Engineering Research Laboratory (ERDC-CERL) was selected for presentation at the 27th Army Science Conference (ASC). The goals of the 27th ASC are to enable Army and DOD leaders, Congress and the public to understand the scope of the Army's science and technology (S&T) activities in support of the Army and the Nation, and to strategically communicate the S&T community's efforts to rapidly develop technologies that will enhance the capabilities of the Current Force while enabling the Future Force.

"The Army Science Conference features presentations that are judged as best among those submitted. We are pleased that ERDC-CERL chose to submit our project as a topic and to be part of the team selected to present the results of our efforts in improving ballistic panel performance using nanocomposite materials" says Dr. Zvi Yaniv, President of Applied Nanotech, Inc.

Ballistic panels are finding increased use as a component in layered protective systems used as fragmentation layers to prevent shrapnel and projectiles from penetrating into areas occupied by troops. A ballistic panel is a composite material made from woven fiberglass fabrics and polymer materials. An improved composite panel material with better bullet resistance to achieve similar performance with a lighter weight panel would benefit the US Army by lowering the weight and volume of material needed to protect critical infrastructure, both domestically and abroad. The team of researchers from US Army ERDC and Applied Nanotech, Inc. will present preliminary results on their effort to improve the ballistic performance of composite panels by incorporating carbon nanotubes in the composite polymer resin. The work is still in progress but the initial results show promise of improved ballistic performance.

"I am pleased that our nanocomposite materials continue to find new markets and are leading to products that will help protect critical infrastructure for both military and civilian applications," said Doug Baker, CEO of ANHI.

About APPLIED NANOTECH HOLDINGS, INC.

Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 250 patents or patents pending. Applied Nanotech's website is www.appliednanotech.net.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: AEGY - Alternative Energy Partners Inc.) LATEST NEWS!! Alternative Energy Partners Establishes Second European Energy Deal AEGY Subsidiary To Provide 20 MW Energy in Europe MERRITT ISLAND, FLORIDA, Jul 29, 2010 -- Alternative Energy Partners (OTCBB: AEGY), provider of comprehensive alternative energy solutions, announces that it is expanding its capabilities in the European green energy market with a significant second deal.

In furtherance of its European energy initiative strategy, Alternative Energy Partners Skynet Energy Systems is entering into an agreement with Suna Energy, Inc. that will allow Skynet to be part of a minimum guaranteed sale of 20MW energy at local prices starting at $0.42/kwh for an estimated 1600 hours per year.

A Letter of Intent for land acquisition and an environmental engineering report are also underway.

This new energy deal is the second European engagement for AEGY. AEGY announced earlier this month that Skynet would have access to obtain Line Reservations in Europe, and thereby provide energy in Europe, including Bulgaria and other FIT (Feed in Tariff) countries. That deal anticipated a delivery of 19.65 MW of energy to surrounding areas.

CEO of Alternative Energy Partners ("AEGY") Gary Reed says, "As I've said before, AEGY feels strongly about the potential for our green energy offerings in the European marketplace. The time is right, and the opportunities are presenting themselves. We look forward to continuing to strategically grow this initiative with an eye on increasing shareholder value while positively affecting the international communities we will be operating in." Earlier in July AEGY announced that Cliff Bream will be joining its Board of Directors. Bream is a graduate of the US Naval Academy as well as The Wharton School at University of Pennsylvania. Formerly an executive with Epson, Xerox, and Cable & Wireless, he has since turned his attention and talents to alternative energy, and is the CEO of Renewable Energy and Water, a California-based developer and systems integrator of renewable energy projects and water reclamation solutions.

About Alternative Energy Partners, Inc.

Alternative Energy Partners is focused on sourcing, marketing and distributing renewable alternative energy solutions. Through its wholly owned subsidiary, Sunarias(TM) Corporation, AEGY provides on-site solar-thermal energy systems that allow businesses to reduce energy costs. It also holds Shovon, LLC, provider of remote control energy managements. AEGY recently announced that through a third subsidiary, Skynet Energy Systems, Inc., it is poised to enter the European alternative energy market. AEGY's goal is to offer a full portfolio of high-performance energy solutions for homes and businesses of all sizes. Alternative Energy Partners is publically traded on the (OTCBB:AEGY). For more information please visit www.aenergypartners.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: NUBL - Numobile, Inc.) LATEST NEWS!! NuMobile to Release Corporate Update Webcast on Year-to-Date Progress and Acquisition Pipeline CARY, NC, Jul 29, 2010 -- NuMobile, Inc. (OTCBB: NUBL) today announced the Company plans to release a corporate update Webcast presentation next Tuesday, August 3rd. The Webcast will provide an update of the Company's progress year-to-date as well as an update on the Company's acquisition pipeline. Last week, NuMobile signed a letter of intent to acquire a mobile cash operation in East Africa that is currently generating approximately $5 million in annual revenue. Last year, NuMobile completed the acquisitions of Stonewall Networks, Inc. and Enhance Network Communication, Inc., software companies with proprietary technology focused on mobile network security.

NuMobile is building a portfolio of security and software solutions for the global mobile computing and smartphone market. Through a roll-up strategy, NuMobile plans to acquire and develop mobile computing solutions for a variety of applications, including mobile banking, for the global marketplace. A link to the on-demand Webcast will be posted to the corporate website www.numobileinc.com upon release.

NuMobile Information and Email Newsletter To learn more about NuMobile and to sign up for company email alerts, please visit the corporate website at www.numobileinc.com.

About NuMobile, Inc.

NuMobile is building a portfolio of security and software solutions for the global mobile computing and smartphone market. Through a roll-up strategy, NuMobile plans to acquire and develop mobile computing solutions for a variety of applications, including mobile banking, for the global marketplace. The demand for mobile security and software applications is being driven in large part by the growing number of mobile phone sales into emerging economies that currently do not have substantial access to the Internet via desktop computing. Already in North America, the Company has also forged a partnership in the Chinese market and is developing a plan for the emerging economies of Latin America and East Africa. NuMobile is a SEC fully-reporting public company listed on the Over-the-Counter Bulletin Board.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: CEMI - Chembio Diagnostics, Inc) LATEST NEWS!! Chembio Reports Second Quarter 2010 Results Conference Call Scheduled for Thursday, July 29, 2010, at 10:30 a.m. Eastern Time MEDFORD, NY, Jul 29, 2010 -- Chembio Diagnostics, Inc. (OTCBB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported its results for the second quarter of 2010. Total revenues were $3.75 million for the three months ended June 30, 2010, which compares to total revenues of $3.37 million for the three months ended June 30, 2009, an 11.1% increase. Revenues for the June 30, 2010 quarter include $.74 million of milestone revenue, which is the first milestone revenue received from Chembio DPP(R) technology. The Company recorded net income of approximately $.62 million, or $0.01 per share, for the three months ended June 30, 2010, compared to net income of approximately $.11 million, or less than $0.01 per share, for the three months ended June 30, 2009. Total revenues were $6.53 million for the six months ended June 30, 2010, which compares to total revenues of $5.92 million for the six months ended June 30, 2009, a 10.4% increase. The Company recorded net income of approximately $.47 million, or $0.01 per share, for the six months ended June 30, 2010, compared to a net loss of approximately $.22 million, or under $0.01 per share, for the six months ended June 30, 2009.

The operating results in the second quarter of 2010 include $1.29 million of revenues from the sale of rapid HIV tests to Alere North America, Inc. ("Alere," formerly Inverness Medical Innovations, Inc.), the Company's exclusive U.S. marketing partner for its two FDA-approved rapid HIV tests. This represents an increase of $.13 million, or 11%, compared to $1.16 million of revenues for the quarter ended June 30, 2009. In the second quarter of 2010, the Company recognized, in the amount of $740,000, its first milestone revenues related to its DPP(R) technology. The Company also realized increased revenues related to research & development contracts and grants, an increase of $.43 million or 158%, to $.70 million in the quarter ended June 30, 2010 from $.27 million in the quarter ended June 30, 2009. The Company increased its research & development expenses in the second quarter of 2010 by $.09 million, or approximately 13% as compared with the same quarter of 2009, in order to service the new contracts and grants and for additional products based on the Company's patented DPP(R) technology being validated for manufacture to enter the clinical evaluation and regulatory approval process.

Commenting on the results, Chembio's President, Lawrence A. Siebert, stated, "The milestones Chembio achieved during the second quarter of 2010, including the license revenues we recorded, provided strong validation of our DPP(R) technology. Our order backlog increased significantly at the end of the second quarter as a result of orders we received from customers in Africa, which we believe should produce at least a 25% increase in product sales from this region in 2010 as compared with 2009, to at least $4.25 million in 2010. This order backlog, combined with continued income from ongoing research and development contracts, and license fees from potential additional product approvals in Brazil during the third quarter, could provide the basis for continued progress in our operating results in 2010." Mr. Siebert continued, "During the recent quarter we also improved our working capital position, with the final payment on the $1.01 million liability to Alere and our obtaining a $500,000 bank facility with HSBC. We also explored the possibility of raising additional equity capital so that we could accelerate our business plan, particularly the pace of our U.S. FDA clinical trials; however acceptable market valuation conditions were not present. We have therefore proceeded more slowly with these expenditures. Nevertheless, given current and anticipated operating cash flow, we believe that even without such additional capital, we will make steady, if not accelerated, progress in executing our business plan." Progress in Product Development & Commercialization for the Quarter Ended June 30, 2010 Oswaldo Cruz Foundation OEM DPP(R) Agreements -- During the second quarter, we received notification from FIOCRUZ that our DPP(R) HIV screening test was approved by Brazil's National Health Surveillance Agency (ANVISA). Two of the other three products, HIV confirmatory and Canine Leishmaniais, have been submitted for, and we believe are, pending Brazilian regulatory approval, which we believe will occur during 2010.

Bio-Rad Laboratories OEM DPP(R) Agreement -- On June 25, 2010, the Company received a letter from Bio-Rad, confirming the completion of Phase 2 (the Development Phase) for the DPP(R) product under our development agreement with Bio-Rad. The completion of the product development phase demonstrates our capability of developing highly accurate multiplex diagnostic devices with our DPP(R).

Battelle/CDC DPP(R) Influenza Immunity Test -- This December 2009 $900,000 development contract is proceeding on schedule, and we plan to send the first prototypes of this product to CDC during the third quarter for evaluation by the CDC.

DPP(R) Hepatitis C and DPP(R) Hepatitis C/HIV Oral Fluid Antibody Tests -- We have received some of the results of the study and have been advised that the remaining data and analysis will be available to all manufacturers that participated with products in the study during the third quarter of 2010. The data and analysis should be useful in helping us to ascertain the performance characteristics of our products in comparison to other products that were in this evaluation.

DPP(R) Influenza -- We have developed a prototype multiplex test for FLU A/B Antigen Detection and have started design work in order to consider further modifications and optimization. Our current plan is for development to be completed and initiation of clinical trials to occur during 2010.

DPP(R) Leptospirosis -- Our work pursuant to this $3 million Phase II NIH grant awarded in June 2009 is progressing on schedule.

Phase II NIH Grant Submission for Tuberculosis -- We were recently informed that based on historical grant approval criteria, there is a substantial likelihood that this $2.7 million Phase II request over three years will be awarded beginning in 2011.

Qualifying Therapeutic Discovery Projects -- In July 2010, we submitted several applications for grants that we believe are eligible Qualifying Therapeutic Discovery Projects, as part of the U.S. Patient Protection And Affordable Care Act of 2010 (P.L. 111-148). The program covers up to 50 percent of a qualified investment made or to be made in 2009 and 2010, limited to a maximum of $5 million per company.

There can be no assurance that any of these grant applications will result in any funding awards to the Company, nor that any of the existing research and development contracts or grants will continue or that they will meet regulatory or any other technical requirements and specifications, and/or that if continued, will result in completed products, or that such products, if they are successfully completed, can or will be successfully commercialized.

Automated Assembly Equipment Installation and Validation -- During the second quarter, we began validation of certain automated assembly equipment for which we received delivery in the first quarter. We believe that, if successfully validated, this equipment may result in savings to our lateral flow and DPP(R) assembly operation. Our plan is to complete this validation during the third quarter of 2010, although there can be no assurance of this.

Patents -- During the second quarter we filed additional patent applications that we believe will strengthen our intellectual property portfolio.

Regulatory Activities CE Mark for FDA approved HIV tests -- Based on the most recent dialog we have had with our Notified Body, we now believe we will be able to meet the CE Marking requirements for our two FDA approved rapid HIV tests, and we have developed an initial budget for this of $76,000, though we believe additional savings can be achieved to bring this cost down further. We are in contact with certain organizations in Europe regarding our acquiring blood donor repository samples, which is the main component of this cost.

Regulatory Approvals in Brazil through the Oswaldo Cruz Foundation (FIOCRUZ) -- We received notification from FIOCRUZ that our DPP(R) HIV screening test was approved by ANVISA for sale by FIOCRUZ in Brazil.

FDA Approval for DPP(R) HIV 1/2 Screening Assay for Oral Fluid -- We have commenced the clinical trials and they have proceeded slowly. We still anticipate completing the clinical trials and submitting the PMA application during 2010, and receiving approval of the PMA before the end of 2011, although there can be no assurance of this. The pace of the clinical trials will depend upon operating cash flow or other financing sources we may pursue, the availability of which there can be no assurance.

DPP(R) Syphilis Screen & Confirm -- We were preparing to commence clinical trials in connection with our planned 510(k) submission for this product during the third quarter of 2010, however we have had some delays in validating the manufacture of lots we need to produce for use in such clinical trials. We have also received some evaluation results from the retrospective international study organized by the WHO which results showed some performance variation from site to site, although the product was still recommended for the prospective phase II of the WHO study.

Discussion of these programs may be included in the Company's conference call this morning.

Financial Highlights for the Quarter ended June 30, 2010 -- Product sales for the quarter ended June 30, 2010 (second quarter) decreased 23.5% to a $2.34 million from $3.05 million in the same period of 2009. Net product sales to Alere for the second quarter increased more than $.13 million to $1.29 million, or approximately 11%, as compared to $1.16 million in the same quarter of 2009. This was offset by decreased sales to Ethiopia and Brazil, as product revenues from our four new programs in Brazil did not yet begin to replace the sales from the 2004 program sales that ended in the first quarter of 2009.

-- We received our first DPP(R) milestone revenues in the second quarter in the amount of $740,000.

-- The increased product, license and R&D revenues in the second quarter of 2010 combined to produce gross margin dollars that were $730,000, or 53.6%, greater ($2.09 million vs. $1.36 million) than the gross margin dollars in the comparable period in 2009.

-- R&D expenses increased by $89,000 in the second quarter of 2010 as compared to the same quarter in 2009. Increases in Wages and related costs and the continuation of clinical trials for our DPP Screen Assay, both contributed to this increase. Net R&D expenses over R&D revenues decreased in the second quarter of 2010 from $433,000 ($703,000 less $270,000) in the 2009 period to $95,000 ($791,000 less $696,000) in the 2010 period.

-- Selling General & Administrative Expenses increased by $138,000 or 25% in the second quarter of 2010 as compared to the second quarter of 2009. This was primarily due to the recording of $60,000 in Brazilian tax withholdings on the milestone payment, an increase in investor relations, an increase in wages and related expenses and an increase in legal, accounting and SOX 404 compliance expenses, partially offset by a decrease in commissions as a result of lower sales in Brazil.

-- Operating income was approximately $623,000, in the second quarter of 2010 as compared to operating income in the second quarter of 2009 of $117,000, an improvement of $506,000. In addition, net income was approximately $622,000 in the second quarter of 2010 as compared to net income in the second quarter of 2009 of $110,000, an improvement of $512,000.

-- The June 30, 2010 cash balance was $321,000 less than as of December 31, 2009. This was primarily due to a $294,000 increase in our DPP inventories, based on product produced in anticipation of approval in Brazil. Also contributing to the cash decrease was a $635,000 decrease in accounts payable balance and a decrease in deferred revenue of $246,000. Non-cash expenses totaled $416,000, and consisted of $148,000 from depreciation expense, $114,000 in share-based compensation expense and $154,000 in the amortization of licenses.

Conference Call Chembio has scheduled a conference call and webcast for 10:30 a.m. Eastern time on Thursday, July 29, 2010. To participate on the conference call, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 6, 2010 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering reservation account number 286 and conference ID #: 354138. The conference call may also be accessed via the internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=160558. An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.

About Chembio Diagnostics Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere North America, Inc. (formerly Inverness Medical Innovations, Inc.) Chembio markets its HIV STAT-PAK(R) line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP(R)) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP(R). Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

For additional information, please contact Steve@StockMarketingInc.com ((Comments on this story may be sent to info@m2.com)) (c) 2010 M2 COMMUNICATIONS

[ Back To Homepage ]